Samsung BioLogics announced on April 10 that it has signed a deal (Binding LOI) with Vir Biotechnology to mass-produce COVID-19 Treatment, worth about $360 million (KRW 440 billion).
Starting with technology transfer this year, Samsung BioLogics will start full-scale production at its third plant in 2021.
Samsung BioLogics' latest production contract for Vir Biotechnology's candidate COVID-19 neutralizing antibody (SARS-CoV-2 mAb) is known to be very powerful in neutralizing the COVID-19.
Vir Biotechnology is a bioscience company based in San Francisco that specializes in developing infectious disease prevention and treatment drugs and is developing a single clone antibody for COVID-19 treatment by separating antibodies from those completely cured from Severe Acute Respiratory Syndrome (SARS), similar to COVID-19.
"We are very pleased that Samsung Biologics has joined the pan-demic response collaboration with unprecedented speed," said George Scangos, CEO of Vir Biotechnology.
"We will do our best to ensure that patients around the world suffering from COVID-19 are supplied with treatments quickly and reliably through global state-of-the-art production facilities owned by Samsung Biologics," said Kim Tae-han, president of Samsung BioLogics.
